The Kirby Laboratory
  • Home
  • Antimicrobials
    • Legionella pneumophila
    • T4SS-dependent Gram negative pathogens
    • CRE Pathogens
    • Mechanisms of carbapenem resistance >
      • Carbapenemases | KPC | NDM-1
      • Porins
      • Efflux pumps
  • Diagnostics
  • SARS-CoV-2
  • Pathogenesis
  • About the PI
  • Personnel
  • Publications
  • Blog
  • Environment
  • Positions
  • Resources
  • Donations
  • Comments
  • Contact Info
  • Internal Lab Resources

Pondering the oddities of companies bringing new antibiotics to market.  Part II.

12/12/2018

0 Comments

 
I attended the 6th Annual Meeting of the Boston Area Resistance Network Meeting this past Friday. A fabulous meeting. Kudos to the organizers. I was particularly riveted by a presentation from Erin Duffy, CSO, of Melinta Pharmaceuticals: "On the design and optimization of pyrrolocytosines." It was a beautiful example of structure-guided design. Melinta was originally called Rib-X Pharmaceuticals. Rib-X was founded on the idea that new drugs could be developed based on the structure of the 50S ribosome (therefore Rib-X) solved by Tom Steitz and Peter Moore. A series of compounds were synthesized to explore a binding site in the 50S ribosome that were not known to be engaged by existing natural products. Therefore, ribosome modifying enzymes conferring resistance through modification of this binding site would presumably not have previously evolved. A point was made of exploring the empty space within the ribosome. I don't remember all of the details, but it went along the lines of by compound 500 had great Gram-positive activity; by compound 1000 had great Gram-negative and Gram-positive activity inclusive of Acinetobacter and Pseudomonas, Interestingly, the molecular characteristics associated with Gram-negative penetrance did not follow eNTRy rules. By compound 2000, toxicity issues had been worked out inclusive of mammalian testing. So seemingly a really promising first in class agent. The final slide for this impressive development effort was a picture of the research group and then a comment that they were all let go the previously week. The company redirected all of its efforts to sales for approved agents and pulled out of discovery efforts. This follows on Achaogen eliminating their discovery program after approval of plazomicin, which follows on Novartis exiting the antibiotic development space. Disconcerting juxtaposition of success and abandonment.
0 Comments

Pondering the oddities of companies bringing new antibiotics to market.  Part I.

12/12/2018

0 Comments

 
New antibiotics that may offer additional and much needed treatment options will only be used in hospital systems if the clinical microbiology laboratory can provide timely antimicrobial susceptibility testing data. Historically there has been a time lag in the availability of susceptibility testing methods either at reference laboratories (long delay to results), incorporation in automated commercial systems (4 years), or simpler methods like disk diffusion and gradient strips that can be performed manually on an as needed basis.  I was excited to learn that delafloxacin and meropenem/vaborbactam disk diffusion and gradient strip methods finally became available. Fantastic. However, before we can introduce those methods in the clinical laboratory, we need to validate performance of these methods per CLIA '88 regulations and good laboratory practice.  This requires either comparing the new methods to a reference standard (broth microdilution -- need antibiotic powder, and a lot of set up time) or a set of strains that has been previously characterized by a reference dilution method and has a good representation of susceptible and resistant isolates.  Those are serious roadblocks.  By chance, I happened to give a talk at the Northeast Branch of the American Society of Microbiology and a someone from Melinta Pharmaceuticals happened to be there, and that someone referred me to our local Key Account Manager who offerred a solution "on request". Specifically, Melinta or other pharmaceutical companies are not allowed to approach me and tell me about a solution, but if I inquire independently and ask for a previously characterized set of bacterial isolates, they are allowed to tell me that in fact they have a series of previously characterized isolates for both drugs available for validation. These isolates are provided free of charge from Laboratory Specialist, Inc, Sent by FEDEX with first class documentation, data for broth microdilution performed circa ten times on each isolates with modal MICs and MIC distribution - wow, that is awesome. Methods validated beautifully. It just seems odd to me that such a valuable resource, providing clinical laboratories the ability to robustly evaluate AST methods for newly marketed drugs, needs to remain on a need to know basis. Clinical labs, please take note of this available resource. The same proved to be true for plazomicin.  Achaogen uses the same Laboratory Specialists, Inc. to provide 30 characterized isolates on request; however, the FEDEX chargers are not absorbed. The FDA-CDC Biobank also now has a set of isolates characterized for plazomicin susceptibility and I see now also delafloxacin., I suspect the exact same set of organisms. The existing rule restricting such company-clinical laboratory communication about these important resources should be relaxed! We need facile access to validation strains sets to bring new testing into our laboratories in a timely fashion, to facilitate the availability of new antibiotics when they are most needed, and to help support profitability of antibiotic development by pharmaceutical companies.      
0 Comments

    Kirby Lab Blog

    ​

    Follow @KirbyLabMicrobe

    RSS Feed

    Categories

    All
    Acinetobacter
    Antibiotics
    Antimicrobial Resistance
    Antimicrobial Susceptibility Testing
    Apramycin
    Artificial Intelligence
    ASM Blog
    Awards
    Brucella
    Candida Auris
    Carbapenem-Resistant Acinetobacter Baumannii (CRAB)
    Carbapenem Resistant Enterobacteriaceae
    Carbapenem-Resistant Enterobacteriaceae
    Clinical Microbiology
    Colistin
    Collaborations
    Images
    Inkjet Printing Diagnostics
    Inoculum Effect
    Klebsiella
    Lab Activities
    Lab Member News
    Legionella
    Manuscripts
    Medicinal Chemistry
    Meetings
    Microbiology And Society
    Microbiology General Interest
    MRSA
    News Release
    Postdoctoral Research
    Post Graduate Research
    Post-Graduate Research
    Staphylococcus Aureus
    Synergy
    Type IV Secretion System
    Undergraduate Research
    VISA

    Archives

    March 2023
    February 2023
    December 2022
    August 2022
    April 2022
    January 2022
    December 2021
    September 2021
    July 2021
    April 2021
    March 2021
    February 2021
    January 2021
    November 2020
    September 2020
    July 2020
    May 2020
    April 2020
    March 2020
    February 2020
    November 2019
    October 2019
    September 2019
    July 2019
    June 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    March 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    December 2014

    Antimicrobials
    Diagnostics
    Pathogenesis
    About the PI
    Personnnel
    Donate
  • Home
  • Antimicrobials
    • Legionella pneumophila
    • T4SS-dependent Gram negative pathogens
    • CRE Pathogens
    • Mechanisms of carbapenem resistance >
      • Carbapenemases | KPC | NDM-1
      • Porins
      • Efflux pumps
  • Diagnostics
  • SARS-CoV-2
  • Pathogenesis
  • About the PI
  • Personnel
  • Publications
  • Blog
  • Environment
  • Positions
  • Resources
  • Donations
  • Comments
  • Contact Info
  • Internal Lab Resources